Introduction
============

Discogenic low back pain is nonradicular and occurs in the absence of spinal deformity, instability, and signs of nerve root irritation, and arises from the disc itself. Its mechanism of production is uncertain.[@b1-jpr-5-381]--[@b3-jpr-5-381] In the absence of evidence of disc herniation, it may be impossible to localize a painful disc from the symptoms and signs elicited on physical examination. Axial low back pain without radiculitis is similar to the pain produced by zygapophyseal joints, the sacroiliac joint, or a musculoligamentous origin of pain.[@b4-jpr-5-381]--[@b14-jpr-5-381] In fact, a year after the description of lumbar disc herniation as causation of low back and lower extremity pain by Mixter and Barr,[@b15-jpr-5-381] Mixter and Ayers[@b16-jpr-5-381] showed that radicular pain can occur without disc herniation. Multiple studies have found that lumbar disc herniation is not the major cause of low back pain, and that discogenic pain caused by annular disruption is one of the most important causes.[@b17-jpr-5-381],[@b18-jpr-5-381] The complex mechanism of discogenic pain has been well described, with chemical nociception leading to low back pain without disc herniation, along with internal disc disruption.[@b1-jpr-5-381],[@b4-jpr-5-381],[@b7-jpr-5-381],[@b8-jpr-5-381],[@b19-jpr-5-381]--[@b24-jpr-5-381] The research in animals has shown that upregulation of various pain-regulated molecules, such as calcitonin gene-related peptide and substance P, in the dorsal root ganglion neurons innervates degenerated intervertebral discs.[@b25-jpr-5-381],[@b26-jpr-5-381] Nonspecific low back pain constitutes 80%--90% of low back pain without identifiable causes, with a large proportion having chronic axial low back pain secondary to progressive degenerative disc disease.[@b1-jpr-5-381],[@b5-jpr-5-381],[@b6-jpr-5-381],[@b8-jpr-5-381],[@b27-jpr-5-381],[@b28-jpr-5-381] Further, the majority of patients with axial low back pain improve with conservative management, and various types of interventions described provide highly variable and mostly poor outcomes.[@b28-jpr-5-381]--[@b40-jpr-5-381]

Even though not well known, and continually debated, epidural injections are one of the most common interventions performed for managing axial low back pain without disc herniation.[@b37-jpr-5-381],[@b38-jpr-5-381],[@b40-jpr-5-381]--[@b51-jpr-5-381] Despite emerging evidence,[@b37-jpr-5-381],[@b38-jpr-5-381],[@b45-jpr-5-381]--[@b61-jpr-5-381] epidural injections in general, and their role in managing axial or discogenic low back pain in particular, have been questioned.[@b37-jpr-5-381],[@b38-jpr-5-381],[@b40-jpr-5-381],[@b42-jpr-5-381],[@b43-jpr-5-381],[@b45-jpr-5-381],[@b62-jpr-5-381]--[@b64-jpr-5-381] However, in evaluating axial low back pain, some studies have failed to rule out facet joint, sacroiliac joint, or other sources of pain prior to treating with epidural injections.

This study sought to evaluate the role of caudal epidural injections in patients with chronic low back pain without disc herniation, radiculitis, facet joint pain, sacroiliac joint pain, or other sources of chronic low back pain who were shown to be negative for facet joint and sacroiliac joint pain by controlled comparative local anesthetic blocks; myofascial pain was ruled out by physical examination. This report is the final report of 120 patients at 2-year follow-up, after a previous preliminary publication,[@b65-jpr-5-381] and one-year follow-up report.[@b37-jpr-5-381]

Materials and methods
=====================

This randomized, double-blind, controlled trial was conducted in the US in a private interventional pain practice and specialty referral center based on Consolidated Standards of Reporting Trials guidelines.[@b66-jpr-5-381] The protocol was approved by the local institutional review board, and registered with the US Clinical Trial Registry (NCT00370799). The study was conducted within the principles of the Declaration of Helsinki, with informed consent approved by the institutional review board and signed by all participants. This study was conducted with the internal resources of the practice without any external funding either from industry or elsewhere. All participants received the protocol and informed consent form approved by the institutional review board, detailing all aspects of the study and the withdrawal process.

Interventions
-------------

Participants were recruited from new patients presenting for interventional pain management. A total of 120 participants were assigned to one of two groups, with group 1 patients receiving caudal epidural injections with local anesthetic (lidocaine 0.5%, 10 mL) and group 2 patients received caudal epidural injections with 9 mL of 0.5% lidocaine mixed with 1 mL of steroid (either brand name or nonparticulate betamethasone \[6 mg\] or methylprednisolone \[40 mg\]). Each injection was flushed with a 2 mL solution of 0.9% sodium chloride solution.

Pre-enrollment evaluation
-------------------------

Controlled comparative local anesthetic blocks were performed during a pre-enrollment evaluation to exclude facet joint or sacroiliac joint pain. Patient demographic data, medical and surgical history with coexisting disease(s), radiologic investigations, physical examination, pain rating scores using the Numeric Rating Scale (NRS), functional status assessment by Oswestry Disability Index 2.0 (ODI), work status, and opioid intake were collected.

Inclusion criteria
------------------

Participants in this trial met all inclusion criteria including: no evidence of disc herniation and a negative diagnosis of lumbar facet joint pain and sacroiliac joint pain by means of controlled local anesthetic blocks; being at least 18 years of age; a history of chronic function-limiting low back pain of at least 6 months' duration; competent to understand the study protocol and provide voluntary, written, informed consent as well as participate in outcome measurements; and failure to improve substantially with conservative management, including but not limited to physical therapy, chiropractic manipulation, exercises, drug therapy, and bedrest.

Exclusion criteria
------------------

Patients with facet joint pain; previous lumbar surgery; uncontrolled or unstable opioid use; uncontrolled psychiatric disorders; uncontrolled medical illness, either acute or chronic; and any other conditions that could interfere with the interpretation of outcome assessments, including pregnant or lactating women, and participants with a history or potential for an adverse reaction or reactions to either local anesthetics, steroids, or both, were excluded.

Description of interventions
----------------------------

Controlled comparative local anesthetic facet joint nerve blocks were performed on all participants. First, diagnostic facet joint nerve blocks were conducted with 0.5 mL of 1% lidocaine. Then, on separate occasions, blockade of facet joint nerves was conducted with 0.25% bupivacaine.[@b4-jpr-5-381],[@b67-jpr-5-381] A response was considered negative if pain relief lasted less than 2 hours following lidocaine injection, and lasted less than 3 hours or less than the duration of relief with lidocaine when bupivacaine was used. Diagnostic sacroiliac joint blocks were performed utilizing 2 mL of 1% lidocaine or 0.25% bupivacaine.

A physician performed the caudal epidural procedures in a sterile operating room located in an ambulatory surgery setting, using fluoroscopy. Participants were in the prone position and were monitored appropriately with intravenous access. Midazolam and/or fentanyl were administered if indicated. After confirmation of entry into the epidural space by injection of nonionic contrast medium, the assigned solution was injected.

Additional interventions
------------------------

Treatments were given to participants as assigned. Upon request, or if an emergency situation arose, a patient was unblinded. Based on a patient's response to prior caudal epidural injections and improvement in physical and functional status, repeat caudal epidural injections were performed when increased levels of pain were reported with deteriorating relief below 50%. However, nonresponsive participants were treated with conservative management and were followed without further epidural injections with medical management, without unblinding. Conservative management with appropriate drug therapy and a therapeutic exercise program were continued as needed, along with work. There were no other interventions. The objective of this study was to investigate the effectiveness of caudal epidural injections with or without steroids in patients with chronic axial low back pain not caused by disc herniation, radiculitis, or facet joint pain.

Outcomes
--------

Multiple outcome measures were used, including NRS pain scale (0--10), ODI (0--50) for functional assessment, employment status, and morphine-equivalent opioid use at 3, 6, 12, 18, and 24 months. The accuracy of the NRS and ODI has been established.[@b68-jpr-5-381] A primary outcome measure of significant pain relief and improvement with 50% or more reduction in NRS from baseline and 50% reduction in the ODI was utilized.[@b38-jpr-5-381],[@b48-jpr-5-381]--[@b57-jpr-5-381],[@b69-jpr-5-381]--[@b71-jpr-5-381] Categories for employment and work status included employable, retired, over age 65 years, or housewife with no desire to work outside the home. Participants who, because of pain, were unemployed, on sick leave but employed, or laid off were considered as employable. Thus, the criteria for work status were based on the type of work status if they were employable or not. Morphine equivalency was utilized to evaluate opioid usage.[@b72-jpr-5-381]

Sample size and randomization
-----------------------------

The sample size was calculated based on significant pain relief. Considering a 0.05 two-sided significance level, a power of 80%, and an allocation ratio of 1:1, 55 participants in each group were estimated to be necessary.[@b73-jpr-5-381] Allowing for a 10% attrition/noncompliance rate, 60 participants were required. Each group was randomly assigned 60 participants. Computer-generated random allocation sequence by simple randomization was utilized. The nurse coordinator, without knowledge of the patient, physician, or other personnel, completed the randomization and drug preparation. All patients meeting the inclusion criteria were invited to participate. They were enrolled and assigned to a group by a nurse coordinator. Group assignments were blinded to participants and the interventional investigators. Study participants were mixed with routine treatment patients.

Statistical methods
-------------------

Data analyses were carried out using the Statistical Package for Social Sciences version 9.01 (SPSS Inc, Chicago, IL). For categorical and continuous data comparison, Chi-squared statistics, Fisher's Exact test, one-way analysis of variance, *t*-tests, and paired *t*-tests were the statistical analyses used. Because the outcome measures of the participants were measured at six points in time, repeated-measures analysis of variance was performed with the post hoc analysis. A *P* value of less than 0.05 was considered to be statistically significant. Initially, three subgroups of participants receiving steroids in group 2 were analyzed for any differences. If no significant differences were observed, the results were presented as a single group. A sensitivity analysis with changes in the NRS was performed utilizing the last follow-up score, best case scenario, and worst case scenario if there were no significant differences; the intention-to-treat analysis by last follow-up visit was used.

Results
=======

[Figure 1](#f1-jpr-5-381){ref-type="fig"} illustrates the participant flow. The enrollment period lasted from January 2007 to August 2008. Baseline characteristics are illustrated in [Table 1](#t1-jpr-5-381){ref-type="table"}. There were significant differences in relation to distribution of gender, age, and mean height. However, even though these are significant, they are not expected to be the cause of any differences. The proportion of women was higher in group 1 compared with group 2. Patients in group 1 were slightly older than the ones in group 2; in addition, mean height was slightly higher in group 2. Intention-to-treat analysis was carried out by last follow-up data, as there were no differences noted with sensitivity analysis.

The epidural injections were considered successful if the patient experienced at least 3 weeks of pain relief with the initial two procedures. A failure was any other result. [Table 2](#t2-jpr-5-381){ref-type="table"} illustrates these results. Over the 2-year study period, group 1 had mean overall pain relief of 46.7 ± 38.3 weeks, and group 2 had 58.3 ± 38.0 weeks. However, when participants were separated into successful and failed groups, the successful participants' total number of procedures per year was 5.7 ± 2.3 in group 1 and 6.4 ± 2.0 in group 2, with relief of 69.7 ± 28.8 weeks in group 1 and 76.1 ± 27.4 weeks in group 2; 37 of 60 participants (62%) in group 1 and 41 of 60 participants (68%) in group 2 had improvement.

Outcomes
--------

[Table 3](#t3-jpr-5-381){ref-type="table"} presents the results of repeated-measures analysis. There were significant differences in participants' average pain scores within-group by time (*P* \< 0.0001), and no significant differences between the two groups (*P* = 0.525). In the ODI for functional status, there were significant differences in summary scores within-group by time (*P* = 0.001) and no significant differences between two groups (*P* = 0.209). Paired-samples *t*-test analysis indicates that mean differences at baseline and the other five time points within the group were significant at the 0.05 level. [Figure 2](#f2-jpr-5-381){ref-type="fig"} illustrates the proportion of participants with a significant change in pain and function. Employment characteristics are shown in [Table 4](#t4-jpr-5-381){ref-type="table"}. Employment increased from a baseline of 62.5% in group 1 and 60% in group 2 to 100% in group 1 and 95% in group 2. Opioid intake is illustrated in [Table 5](#t5-jpr-5-381){ref-type="table"}, showing no significant differences. [Table 6](#t6-jpr-5-381){ref-type="table"} shows no significant weight change in either group. None of the patients reported significant adverse events during the study period.

Discussion
==========

Evaluation of a 2-year follow-up with 120 participants showed significant pain relief and improvement of functional status in a select group of patients, who were judged to be successful at 84% in group 1 and 73% in group 2. However, the results were significant even with inclusion of all participants, with successful outcome with 54% in group 1 and 60% in group 2 at the end of 2 years. The total number of procedures in the successful category was 5.7 ± 2.3 in group 1 and 6.4 ± 2.0 in group 2. Further, in the successful category, the total relief over the 2-year study period was for 69.7 ± 28.8 weeks in group 1 and 76.1 ± 27.4 weeks in group 2. There was no significant change in opioid intake. In reference to employment, all of the participants in group 1 and 95% in group 2 who were eligible for employment were employed at the end of 2 years. As expected, the failed group showed inconsistent and inadequate relief. Further, this study illustrates that relief is limited in the majority of patients; the mean relief was approximately 13 weeks after the first two procedures. Consequently, well selected patients may respond on a long-term basis, but only with judicious repeat therapy. There were no significant differences when a steroid was used or according to what type of steroid was used among the three types of steroids.

The literature is replete with multiple studies and systematic reviews of epidural injections; however, there is a paucity of literature and evidence for managing axial or discogenic pain.[@b24-jpr-5-381],[@b37-jpr-5-381],[@b38-jpr-5-381],[@b40-jpr-5-381]--[@b43-jpr-5-381],[@b45-jpr-5-381]--[@b50-jpr-5-381] There has been only one randomized controlled trial[@b37-jpr-5-381],[@b65-jpr-5-381] and one nonrandomized study[@b46-jpr-5-381] evaluating axial low back pain of presumably discogenic origin utilizing fluoroscopic epidural injections. In general, the studies have been criticized for their designs and their inability to confirm the injection of the injectate without using fluoroscopy. In addition, systematic reviews have also faced criticism for their methodology and inclusion of inappropriate studies leading to inaccurate conclusions.[@b24-jpr-5-381],[@b40-jpr-5-381],[@b44-jpr-5-381],[@b45-jpr-5-381],[@b63-jpr-5-381],[@b64-jpr-5-381],[@b74-jpr-5-381]--[@b77-jpr-5-381] Even the recent study published with a placebo design for caudal epidural injections in evaluating the role in disc herniation[@b62-jpr-5-381] was met with significant criticism.[@b78-jpr-5-381],[@b79-jpr-5-381] Only one study, by Ghahreman et al,[@b80-jpr-5-381] which had a proper placebo-controlled design, has showed no significant effect with sodium chloride solution when injected into an inactive structure. Instead of fluoroscopy, Iverson et al[@b62-jpr-5-381] utilized ultrasound and showed negative results, and their study has been criticized for flaws related to design, conduct, patient selection, and interpretation of results. In an editorial by Cohen[@b81-jpr-5-381] in response to the Iverson el al[@b62-jpr-5-381] study, Cohen concluded that while epidural injections provide only modest improvement in carefully selected patients, they were considered as an effective adjunct when used judiciously. Thus, in the era of comparative effectiveness research,[@b74-jpr-5-381],[@b75-jpr-5-381],[@b77-jpr-5-381],[@b78-jpr-5-381],[@b82-jpr-5-381] the evidence from comparative effectiveness or active controlled trials, which include the present study, are crucial in clinical interpretation and intervention.

In patients suffering with chronic low back pain, when utilizing controlled diagnostic blocks, the prevalence of pain due to internal disc disruption has been reported to be 39%,[@b8-jpr-5-381] and primary discogenic pain has been reported in 26%[@b7-jpr-5-381] when no other cause was suspected. In the absence of disc herniation or radicular pain, facet joint pain has been shown to be present in 21%--40% of patients,[@b4-jpr-5-381],[@b24-jpr-5-381] whereas sacroiliac joint pain has been established in 10%--27% of the population.[@b4-jpr-5-381],[@b24-jpr-5-381] Thus, discogenic pain may be diagnosed without discography by eliminating all other structures responsible for pain in axial low back pain even when there are no abnormalities noted in the disc and there is no disc herniation or neural compression identified.

This study may be criticized for its lack of a placebo group. However, in recent years, comparative effectiveness research has been considered as pivotal to evidence-based medicine.[@b74-jpr-5-381],[@b75-jpr-5-381],[@b77-jpr-5-381],[@b78-jpr-5-381],[@b82-jpr-5-381] Even though the current study is limited to a single center, and is an active controlled trial, it is also double-blind and designed to determine whether fluoroscopically directed epidural injections with or without steroids with the usual volumes injected in practice are helpful or not. Consequently, the results of this trial are practical and applicable for interventional pain management settings, highlighting the importance of patient selection and the mode of management with contemporary interventional pain management, with repeat procedures only when the pain returns. Placebo control is a difficult aspect of interventional techniques. A placebo injection into an active structure can lead to various types of effects, including a nocebo effect.[@b83-jpr-5-381]--[@b90-jpr-5-381] Further, misguided attempts to classify local anesthetic injections as placebo also have no basis, considering the mechanism of action of local anesthetics and steroids and recent publications indicating significant effectiveness for local anesthetic injections, similar to steroids.[@b24-jpr-5-381],[@b38-jpr-5-381],[@b46-jpr-5-381],[@b48-jpr-5-381]--[@b57-jpr-5-381],[@b69-jpr-5-381]--[@b71-jpr-5-381],[@b91-jpr-5-381]--[@b95-jpr-5-381]

The results of the present study describe participants in a private interventional pain management practice setting. Consequently, the results are not applicable to the general population unless the same methodology is utilized with regard to the diagnosis and therapy. Further, the generalizability of the findings of this study might only be feasible in studies utilizing larger populations in multiple settings.

Overall, the evidence in this report demonstrates caudal epidural injections in participants negative for lumbar facet joint pain, without disc herniation or radiculitis, may be treated with caudal epidural injections with or without steroids, providing approximately 12 weeks of relief with each procedure and requiring 3--4 treatments per year and six treatments per 2 years.

Conclusion
==========

The assessment of the 2-year results of this randomized, double-blind, controlled trial of caudal epidural injections in chronic function-limiting low back pain without facet joint pain, disc herniation, and/or radiculitis, demonstrated effectiveness in 84% of participants with local anesthetic only and 73% of participants with local anesthetic and steroids, providing significant pain relief and improvement in functional status in the successful groups at 24 months.
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###### 

Baseline demographic characteristics

                               Group 1 (n = 60)   Group 2 (n = 60)   *P* value
  ---------------------------- ------------------ ------------------ -----------
  Gender                                                             
   Male                        22% (13)           37% (22)           0.071
   Female                      78% (47)           63% (38)           
  Age, years                                                         
   Mean ± SD                   48.5 ± 15.3        43.9 ± 13.1        0.08
  Weight (lbs)                                                       
   Mean ± SD                   189.5 ± 59.6       177.1 ± 42.5       0.190
  Height (inches)                                                    
   Mean ± SD                   64.8 ± 3.7         66.3 ± 3.6         0.025
  Duration of pain (months)                                          
   Mean ± SD                   100 ± 87.0         92 ± 85.4          0.611
  Onset of pain                                                      
   Gradual                     70% (42)           60% (36)           0.339
   Injury                      30% (18)           40% (24)           
  Low back pain distribution                                         
   Bilateral                   83% (50)           83% (50)           1.000
   Left or right               17% (10)           17% (10)           
  Numeric Rating Score                                               
   Mean ± SD                   8.0 ± 0.9          7.9 ± 1.0          0.374
  Oswestry Disability Index                                          
   Mean ± SD                   28.3 ± 4.92        28.4 ± 4.67        0.939

**Abbreviation:** SD, standard deviation.

###### 

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 2 years for back pain

                                                                   Successful participants                               Failed participants   Combined                                                                         
  ---------------------------------------------------------------- ----------------------------------------------------- --------------------- ------------ ------------- ----------------------------------------------------- -------------
  Average number of procedures first year                          3.8[\#](#tfn3-jpr-5-381){ref-type="table-fn"} ± 0.9   4.3 ± 0.9             2.5 ± 1.3    3.1 ± 1.6     3.3[\#](#tfn3-jpr-5-381){ref-type="table-fn"} ± 1.3   3.9 ± 1.3
  Average number of procedures over two years                      5.7 ± 2.3                                             6.4 ± 2.0             2.7 ± 1.6    3.6 ± 2.4     4.5[\#](#tfn3-jpr-5-381){ref-type="table-fn"} ± 2.5   5.5 ± 2.5
  Average relief per procedure for initial 2 procedures in weeks   9.6 ± 6.5                                             9.5 ± 11.4            1.9 ± 2.1    1.7 ± 2.2     6.9 ± 6.5                                             7.1 ± 10.3
  Average relief per procedure after initial 2 procedures          13.8 ± 6.8                                            13.1 ± 7.5            7.2 ± 5.6    9.7 ± 5.8     13.0 ± 7.0                                            12.6 ± 7.3
  Average relief per procedure                                     12.3 ± 7.0                                            12.0 ± 9.0            3.7 ± 4.4    5.6 ± 5.9     10.4 ± 7.4                                            10.6 ± 8.9
  Average total relief first year (weeks)                          40.8 ± 9.4                                            43.1 ± 10.2           7.9 ± 10.4   12.9 ± 13.9   28.2 ± 18.8                                           33.5 ± 18.2
  Average total relief over 2 years (weeks)                        69.7 ± 28.8                                           76.1 ± 27.4           9.6 ± 16.0   19.9 ± 28.1   46.7 ± 38.3                                           58.3 ± 38.0

**Notes:**

Indicates significant difference versus group 2 (*P* \< 0.05); Successful participant, at least one week relief at first injection and ≥4 weeks relief at second injection.

###### 

Comparison of numeric pain rating scale for pain and oswestry disability index score summaries at six time points

  Time points                 Mean ± SD                                                                                                                                                                            
  --------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------
  Baseline                    8.0 ± 0.9                                                   7.9 ± 1.0                                                   28.3 ± 4.9                                                   28.4 ± 4.7
  3 months                    4.2[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.8 (68%)   3.6[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.4 (80%)   16.3[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 7.2 (60%)   14.5[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 5.5 (75%)
  6 months                    4.1[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.8 (68%)   3.7[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.5 (80%)   16.4[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 7.4 (62%)   14.3[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 5.9 (75%)
  12 months                   4.3[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.8 (63%)   3.8[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.6 (72%)   16.4[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 7.6 (56%)   14.5[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 6.1 (72%)
  18 months                   4.4[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.9 (60%)   3.9[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.9 (68%)   16.5[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 7.7 (56%)   14.5[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 6.3 (67%)
  24 months                   4.4[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.9 (57%)   4.0[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 1.7 (65%)   16.5[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 7.7 (56%)   14.9[\*](#tfn5-jpr-5-381){ref-type="table-fn"} ± 6.4 (63%)
  Group difference            0.525                                                       0.209                                                                                                                    
  Time difference             0.001                                                       0.001                                                                                                                    
  Group by time interaction   0.104                                                       0.162                                                                                                                    

**Notes:** A lower value indicates better condition;

Significant difference with baseline values within the group (*P* \< 0.05); Numbers in parentheses illustrate proportion with significant pain relief (≥50%) from baseline.

###### 

Employment characteristics

                             Group 1   Group 2        
  -------------------------- --------- --------- ---- ----
  Employed part-time         4         3         2    4
  Employed full-time         6         14        10   15
  Unemployed                 6         2         8    4
  Total employed             10        17        12   19
  Eligible for employment    16        16        20   20
  Housewife                  7         4         5    2
  Disabled                   29        29        33   33
  Over 65 years of age       8         8         2    2
  Total number of patients   60        60        60   60

###### 

Opioid intake (morphine equivalents in mg)

  Opioid intake (morphine equivalence mg)   Mean ± SD     
  ----------------------------------------- ------------- -------------
  Baseline                                  34.5 ± 33.7   36.2 ± 19.8
  3 months                                  28.7 ± 27.1   29.9 ± 19.9
  6 months                                  31.5 ± 38.4   31.0 ± 19.9
  12 months                                 31.5 ± 38.4   30.0 ± 19.9
  18 months                                 31.0 ± 38.4   29.8 ± 20.3
  24 months                                 31.0 ± 38.4   29.8 ± 20.3
  Group difference                          0.453         
  Time difference                           0.165         
  Group by time interaction                 0.959         

###### 

Characteristics of changes in weight

  Weight (lbs)          Mean ± SD      *P* value      
  --------------------- -------------- -------------- -------
  Weight at beginning   189.5 ± 59.6   177.1 ± 42.5   0.191
  Weight at 24 months   187.0 ± 58.1   177.1 ± 43.5   0.290
  Change                −2.5 ± 13.6    0 ± 10.9       0.273
  Lost weight           45% (27)       47% (28)       0.161
  No change             20% (12)       8% (5)         
  Gained weight         35% (21)       45% (27)       

**Abbreviation:** SD, standard deviation.
